26 Results for "

Rho pathways

" in MedChemExpress (MCE) Product Catalog:
Products (26)

26 Results for "Rho pathways" in MCE Product Catalog:

Cat. No.: HY-13991R
CAS No.: 285986-88-1
Target:  

Ras Apoptosis

Research Areas:  

Cancer

CCG-1423 (Standard) is the analytical standard of CCG-1423. This product is intended for research and analytical applications. CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
loading...
    loading...
Cat. No.: HY-105284R
CAS No.: 120788-07-0
Synonyms: CP-70429 (Standard)
N-Acetylneuraminic acid (Standard) is the analytical standard of N-Acetylneuraminic acid. This product is intended for research and analytical applications. N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
loading...
    loading...
Cat. No.: HY-P10393
CAS No.: 938077-77-1
Synonyms: ERα (295-311)
Target:  

Apoptosis

Research Areas:  

Cancer

ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .
loading...
    loading...
Cat. No.: HY-B0515R
CAS No.: 138926-19-9
Synonyms: BM-210955 (Standard); RPR-102289A (Standard)
Research Areas:  

Cancer

Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) (Standard) is the analytical standard of Ibandronate Sodium Monohydrate (HY-B0515). This product is intended for research and analytical applications. Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
loading...
    loading...
Cat. No.: HY-108361R
CAS No.: 1443437-74-8
Target:  

Reference Standards Ras

Research Areas:  

Inflammation/Immunology Cancer

CCG-203971 (Standard) is the analytical standard of CCG-203971 (HY-108361). This product is intended for research and analytical applications. CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
loading...
    loading...
Cat. No.: HY-FLB0515
CAS No.: 138926-19-9
Synonyms: BM-210955 solution; RPR-102289A solution
Target:  

Apoptosis

Research Areas:  

Metabolic Disease Cancer

Sodium ibandronate solution is mainly composed of Ibandronate Sodium Monohydrate (HY-B0515).Ibandronate sodium monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate sodium monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate sodium monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate sodium monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
loading...
    loading...